Volume 23 Issue 8
Aug.  2025
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2025  >  23(8): 1298-1302
HAN Shu, DAI Rong, XIE Weinan, WANG Baojia, DI Jiamei. Analysis of PTH compliance and related influencing factors in MHD patients in Huainan area[J]. Chinese Journal of General Practice, 2025, 23(8): 1298-1302. doi: 10.16766/j.cnki.issn.1674-4152.004119
Citation: HAN Shu, DAI Rong, XIE Weinan, WANG Baojia, DI Jiamei. Analysis of PTH compliance and related influencing factors in MHD patients in Huainan area[J]. Chinese Journal of General Practice, 2025, 23(8): 1298-1302. doi: 10.16766/j.cnki.issn.1674-4152.004119
shu

Analysis of PTH compliance and related influencing factors in MHD patients in Huainan area

doi: 10.16766/j.cnki.issn.1674-4152.004119
  • 1.

    Graduate School of Bengbu Medical University, Bengbu, Anhui 233000, China

Funds:

 AHWJ2023A10030

 Byycx23142

  • Received Date: 2025-01-22
    Available Online: 2025-10-31
    Abstract
  •   Objective  To understand the compliance of parathyroid hormone (PTH) quality control indicators and related influencing factors in maintenance hemodialysis (MHD) patients in Huainan area through the analysis of general clinical data and clinical quality control data of MHD patients in Huainan area from 2021 to 2023, so as to provide a basis for finding more effective prevention and treatment measures.  Methods  The patients who underwent MHD in 18 hemodialysis units in Huainan area from January 2021 to December 2023 were selected as the research objects, and the general clinical data and related laboratory indicators of all patients were collected. The compliance of PTH related clinical indicators in MHD patients in Huainan area was analyzed, and the related factors affecting PTH compliance were explored.  Results  A total of 4 409 MHD patients from 18 hemodialysis units in Huainan area were included in this study, including 2 740 males and 1 669 females, with an average age of (58.23±12.71) years and an average dialysis age of 60.00 (36.00, 97.00) months. The laboratory test results of all subjects showed that the compliance rates of serum calcium, serum phosphorus, ALP and PTH were 63.1%, 46.7%, 75.3%, and 59.2%, respectively. There were statistically significant differences in the distribution of blood phosphorus compliance rate and PTH compliance rate in 2021, 2022 and 2023 (χ2=8.765, 10.917, P=0.012, 0.004). There were statistically significant differences in the distribution of PTH compliance among subjects with different ages, primary diseases, blood phosphorus compliance rate and ALP compliance rate (P < 0.05).  Conclusion  The indicators of MHD patients in Huainan area still need to be further improved, and the compliance rate of blood phosphorus and PTH increased year by year from 2021 to 2023. The age, hypertension, serum phosphorus and ALP are all related factors affecting PTH compliance.

     

    • FullText(HTML)
  • loading
    • References(24)
  • [1]
    COLLABORATION G C K D. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2021, 395(10225): 709-733.
    [2]
    XU Y, EVANS M, SORO M, et al. Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease[J]. Clin Kidney J, 2021, 14(10): 2213-2220. doi: 10.1093/ckj/sfab006
    [3]
    NAHID T, ANGELO K, ROBINSON B M, et al. The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation[J]. Nephrol Dial Transplant, 2021, 36(1): 160-169. doi: 10.1093/ndt/gfaa195
    [4]
    KIRNAP N G, KIRNAP M, SAYIN B, et al. Risk factors and treatment options for persistent hyperparathyroidism after kidney transplantation[J]. Transplant Proc, 2020, 52(1): 157-161. doi: 10.1016/j.transproceed.2019.11.020
    [5]
    YU Y, DIAO Z, WANG Y, et al. Hemodialysis patients with low serum parathyroid hormone levels have a poorer prognosis than those with secondary hyperparathyroidism[J]. Ther Adv Endocrinol Metab, 2020, 21(11): 2042018820958322. DOI: 10.1177/2042018820958322.
    [6]
    DANG Z H, TANG C, LI G L, et al. Mineral and bone disorder in hemodialysis patients in the tibetan plateau: a multicenter cross-sectional study[J]. Ren Fail, 2019, 41(1): 636-643. doi: 10.1080/0886022X.2019.1635892
    [7]
    TAO S, LI X, LIU Z, et al. Investigation on maintenance hemodialysis patients with mineral and bone disorder in Anhui province, China[J]. Int Urol Nephrol, 2023, 55(2): 389-398.
    [8]
    YE X, KOOMAN J P, SANDE F M V D, et al. Relationship between serum phosphate levels and survival in chronic hemodialysis patients: interactions with age, malnutrition and inflammation[J]. Clin Kidney J, 2019, 14(1): 348-357.
    [9]
    CIANCIOLO G, TONDOLO F, BARBUTO S, et al. Denosumab-induced hypocalcemia and hyperparathyroidism in de novo kidney transplant recipients[J]. Am J Nephrol, 2021, 52(8): 611-619. doi: 10.1159/000518363
    [10]
    黄梦娣, 陈卫东, 刘磊. 维持性血液透析患者血清碱性磷酸酶与钙磷代谢及炎症指标相关性分析[J]. 中华全科医学, 2023, 21(4): 611-614. doi: 10.16766/j.cnki.issn.1674-4152.002942

    HUANG M D, CHEN W D, LIU L. Correlation analysis of serum alkaline phosphatase with calcium and phosphorus metabolism and inflammatory markers in maintenance hemodialysis patients[J]. Chinese Journal of General Practice, 2023, 21(4): 611-614. doi: 10.16766/j.cnki.issn.1674-4152.002942
    [11]
    CHEN Z, ZHANG X, HAN F, et al. High alkaline phosphatase and low intact parathyroid hormone associate with worse clinical outcome in peritoneal dialysis patients[J]. Perit Dial Int, 2021, 41(2): 236-243. doi: 10.1177/0896860820918131
    [12]
    TSUJIKAWA L M, FU L, DAS S, et al. Apabetalone (RVX-208)reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism[J]. Clin Epigenetics, 2019, 11(1): 102. doi: 10.1186/s13148-019-0696-z
    [13]
    ISERI K, WATANABE M, YOSHIKAWA H, et al. Effects of denosumab and alendronate on bone health and vascular function in hemodialysis patients: a randomized, controlled trial[J]. J Bone Miner Res, 2019, 34(6): 1014-1024. doi: 10.1002/jbmr.3676
    [14]
    SATO M, INABA M, YAMADA S, et al. Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan: an observational study[J]. J Bone Miner Metab, 2021, 39(6): 1082-1090. doi: 10.1007/s00774-021-01253-y
    [15]
    OINONEN L, TIKKAKOSKI A, KOSKELA J, et al. Parathyroid hormone may play a role in the pathophysiology of primary hypertension[J]. Endocr Connect, 2021, 10(1): 54-65. doi: 10.1530/EC-20-0446
    [16]
    MATHUR A, SUTTON W, AHN J B, et al. Association between treatment of secondary hyperparathyroidism and posttransplant outcomes[J]. Transplantation, 2021, 105(12): e366-e374. doi: 10.1097/TP.0000000000003653
    [17]
    KOMABA H, KAKUTA T, WADA T F M, et al. Nutritional status and survival of maintenance hemodialysis patients receiving lanthanum carbonate[J]. Nephrol Dial Transplant, 2019, 34(2): 318-325. doi: 10.1093/ndt/gfy090
    [18]
    MILLA C, WIDODO, WARDHANA T H. The hidden and complex relationship between dietary phosphorus and malnutrition in hemodialysis patients with chronic kidney disease[J]. Rom J Intern Med, 2024, 62(1): 52-60.
    [19]
    CEKIC D, SIPAHI S, EMIR ARMAN M. Proton pump inhibitors with calcium acetate on serum phosphorus levels in hemodialysis patients[J]. Caspian J Intern Med, 2023, 14(4): 737-740.
    [20]
    CUI X, JIANG S, LIU L, et al. Effect of low-dose lanthanum carbonate on calcium and phosphorus metabolism in Asian patients with end-stage renal disease, maintenance hemodialysis and hyperphosphatemia[J]. Afr Health Sci, 2022, 22(2): 362-368. doi: 10.4314/ahs.v22i2.41
    [21]
    DÍAZ-DE LA CRUZ E N, CERRILLOS-GUTIÉRREZ J I, GARCÍA-SÁNCHEZ A, et al. The influence of sevelamer hydrochloride and calcium carbonate on markers of inflammation and oxidative stress in hemodialysis at six months of follow-up[J], Front Med(Lausanne), 2021, 25(8): 714205. DOI: 10.3389/fmed.2021.714205.
    [22]
    MEDAURA J A, ZHOU M, FICOCIELLO L H, et al. Serum phosphorus management with sucroferric oxyhydroxide as a first-line phosphate binder within the first year of hemodialysis[J]. Am J Nephrol, 2024, 55(2): 127-135. doi: 10.1159/000535754
    [23]
    JIANG X, SUN F, HUANG H. Clinical efficacy and long-term prognosis of high flux hemodialysis combined with different frequency hemodiafiltration in the treatment of middle-aged and patients with uremia[J]. Iran J Kidney Dis, 2024, 18(1): 36-44.
    [24]
    SHOKRY G, MORKOS M. Calcium challenge to confirm secondary hyperparathyroidism caused by decreased calcium intake[J]. Endocr Pract, 2022, 28(10): 1069-1071. doi: 10.1016/j.eprac.2022.07.009
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (4) PDF downloads(0) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return